Ensemble is developing a novel class of therapeutics, called Ensemblins™, which open up new ways to treat diseases by addressing drug targets that are currently inaccessible with conventional small molecule drugs. Ensemblins are synthetic macrocycles that have a distinct ring structure, which confers an unprecedented combination of chemical and biologic properties that stretch the therapeutic potential of small molecule drugs. With their unique macrocyclic structure, Ensemblins are a new class of drugs in the emerging therapeutic space between small molecules and biologics. With its proprietary DNA-programmed drug discovery platform, Ensemble is the first company to successfully and reliably engineer synthetic macrocycle drugs, a class of compounds that have traditionally existed principally as natural products but have resulted in over 100 marketed products. In January 2010, Ensemble initiated a strategic alliance with Pfizer Inc. (NYSE: PFE) to discover and develop drug candidates of a novel class against a number of high-value pharmaceutical targets.  Ensemble is a Flagship VentureLabs company.

Noubar Afeyan is a Founder and Chairman of the Board of Directors and Doug Cole is on the Board of Directors.